Osteoporosis

You have full text access to this OnlineOpen article

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six–month results of a randomized, double-blind, controlled trial†

  1. Kenneth G. Saag1,‡,*,
  2. Jose R. Zanchetta2,§,
  3. Jean-Pierre Devogelaer3,¶,
  4. Robert A. Adler4,‖,
  5. Richard Eastell5,††,
  6. Kyoungah See6,‡‡,
  7. John H. Krege6,‡‡,
  8. Kelly Krohn6,‡‡,
  9. Margaret R. Warner6,‡‡

Article first published online: 29 OCT 2009

DOI: 10.1002/art.24879

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 11, pages 3346–3355, November 2009

Additional Information

How to Cite

Saag, K. G., Zanchetta, J. R., Devogelaer, J.-P., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K. and Warner, M. R. (2009), Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six–month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism, 60: 3346–3355. doi: 10.1002/art.24879

Author Information

  1. 1

    University of Alabama at Birmingham

  2. 2

    Universidad del Salvador, Buenos Aires, Argentina

  3. 3

    Université Catholique de Louvain, Brussels, Belgium

  4. 4

    McGuire VAMC, Richmond, Virginia

  5. 5

    University of Sheffield, Sheffield, UK

  6. 6

    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

  1. ‡

    Dr. Saag has received consulting and speaking fees from Novartis (more than $10,000) and from Eli Lilly, Merck, Amgen, Procter & Gamble, and Aventis (less than $10,000 each).

  2. §

    Dr. Zanchetta has received consulting and speaking fees from Amgen, Eli Lilly, Pfizer, and Servier (less than $10,000 each).

  3. Dr. Devogelaer receives research support from Amgen, Eli Lilly, Merck, Nordic Bioscience, Novartis, Pfizer, Procter & Gamble, Sanofi-Aventis, Servier, and Wyeth and speaking fees from Eli Lilly, Novartis, Procter & Gamble, and Servier (less than $10,000 each).

  4. ‖

    Dr. Adler has received speaking and consulting fees from Eli Lilly, Novartis, and Merck (less than $10,000 each), and research support from Eli Lilly, Novartis, and Procter & Gamble.

  5. ††

    Dr. Eastell has received consulting or advisory board fees from Amgen, Novartis, Procter & Gamble, Servier, Ono, and GlaxoSmithKline (less than $10,000 each), lecture fees from Eli Lilly (less than $10,000), and grant support from AstraZeneca, Procter & Gamble, and Novartis (less than $10,000 each).

  6. ‡‡

    Drs. See, Krege, Krohn, and Warner own stock or stock options in Eli Lilly.

*University of Alabama at Birmingham, FOT 820, 1530 Third Avenue South, Birmingham, AL 35294-3408

  1. †

    ClinicalTrials.gov identifier: NCT00051558.

Publication History

  1. Issue published online: 29 OCT 2009
  2. Article first published online: 29 OCT 2009
  3. Manuscript Accepted: 11 JUL 2009
  4. Manuscript Received: 12 DEC 2008

Funded by

  • Eli Lilly and Company

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (125K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    S. Lekamwasam, J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl, J. E. Compston, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis, Osteoporosis International, 2012,

    CrossRef

  2. 2
    S. Lekamwasam, J. D. Adachi, D. Agnusdei, J. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L. C. Hofbauer, J. A. Kanis, B. L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O. D. Messina, N. Napoli, B. Obermayer-Pietsch, S. H. Ralston, P. N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D. A. Wahl, J. E. Compston, An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis, Archives of Osteoporosis, 2012,

    CrossRef

  3. 3
    Sarah K. Gray, Meghan E. McGee-Lawrence, Jennifer L. Sanders, Keith W. Condon, Chung-Jui Tsai, Seth W. Donahue, Black bear parathyroid hormone has greater anabolic effects on trabecular bone in dystrophin-deficient mice than in wild type mice, Bone, 2012,

    CrossRef

  4. 4
    Ann V. Schwartz, Clinical Aspects of Diabetic Bone Disease: An Update, Clinical Reviews in Bone and Mineral Metabolism, 2012,

    CrossRef

  5. 5
    Natalie E. Cusano, John P. Bilezikian, Combination Anabolic and Antiresorptive Therapy for Osteoporosis, Endocrinology and Metabolism Clinics of North America, 2012,

    CrossRef

  6. 6
    Bart L. Clarke, Corticosteroid-Induced Osteoporosis, American Journal of Clinical Dermatology, 2012, 13, 3, 167

    CrossRef

  7. 7
    M. Isabel Almagro, Jorge A. Roman-Blas, Miriam Bellido, Santos Castañeda, Raul Cortez, Gabriel Herrero-Beaumont, PTH [1-34] enhances bone response around titanium implants in a rabbit model of osteoporosis, Clinical Oral Implants Research, 2012, 23, 6
    Direct Link:
  8. 8
    Robert A. Adler, Secondary Fracture Prevention, Current Osteoporosis Reports, 2012, 10, 1, 22

    CrossRef

  9. 9
    Vito Longo, Oronzo Brunetti, Stella D’Oronzo, Franco Dammacco, Franco Silvestris, Therapeutic approaches to myeloma bone disease: An evolving story, Cancer Treatment Reviews, 2012, 38, 6, 787

    CrossRef

  10. 10
    Raj Mitra, Adverse Effects of Corticosteroids on Bone Metabolism: A Review, PM&R, 2011, 3, 5, 466

    CrossRef

  11. 11
    Vit Zikan, Bone Health in Patients with Multiple Sclerosis, Journal of Osteoporosis, 2011, 2011, 1

    CrossRef

  12. You have free access to this content12
    Juliet Compston, Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?, Clinical Endocrinology, 2011, 74, 5
    Direct Link:
  13. 13
    Natalie E. Cusano, John P. Bilezikian, Combination antiresorptive and osteoanabolic therapy for osteoporosis: We are not there yet, Current Medical Research and Opinion, 2011, 27, 9, 1705

    CrossRef

  14. 14
    Ali Guermazi, David J. Hunter, Ling Li, Olivier Benichou, Felix Eckstein, C. Kent Kwoh, Michael Nevitt, Daichi Hayashi, Different thresholds for detecting osteophytes and joint space narrowing exist between the site investigators and the centralized reader in a multicenter knee osteoarthritis study—data from the Osteoarthritis Initiative, Skeletal Radiology, 2011, 41, 2, 179

    CrossRef

  15. 15
    Andrew J. Laster, S. Bobo Tanner, Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?, Rheumatic Disease Clinics of North America, 2011, 37, 3, 323

    CrossRef

  16. 16
    Mika Tsujimoto, Kazunori Uenaka, Atsuko Iwata, Yoshihiro Higashiuchi, Hideaki Sowa, Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy, Journal of Bone and Mineral Metabolism, 2011, 30, 3, 326

    CrossRef

  17. 17
    M. Wong, X. Wan, V. Ruff, K. Krohn, K. Taylor, Gender differences for initiating teriparatide therapy: Baseline Data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study, Osteoporosis International, 2011, 23, 4, 1445

    CrossRef

  18. 18
    Feng-Sheng Wang, Re-Wen Wu, Jih-Yang Ko, Ming-Hong Tai, Huei-Ching Ke, Da-Wei Yeh, Shin-Long Wu, Ming-Wen Chen, Heat shock protein 60 protects skeletal tissue against glucocorticoid-induced bone mass loss by regulating osteoblast survival, Bone, 2011, 49, 5, 1080

    CrossRef

  19. 19
    G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis, Endocrine, 2011, 41, 1, 58

    CrossRef

  20. 20
    Edward S. Leib, Kenneth G. Saag, Jonathan D. Adachi, Piet P. Geusens, Neil Binkley, Eugene V. McCloskey, Didier B. Hans, Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture, Journal of Clinical Densitometry, 2011, 14, 3, 212

    CrossRef

  21. 21
    Béatrice Bouvard, Erick Legrand, Maurice Audran, Daniel Chappard, Ostéoporose secondaire à la corticothérapie systémique, Revue du Rhumatisme Monographies, 2011, 78, 2, 69

    CrossRef

  22. 22
    C. Marcelli, Osteoporosis inducida por corticoides, EMC - Aparato Locomotor, 2011, 44, 4, 1

    CrossRef

  23. 23
    Marius E. Kraenzlin, Christian Meier, Parathyroid hormone analogues in the treatment of osteoporosis, Nature Reviews Endocrinology, 2011, 7, 11, 647

    CrossRef

  24. 24
    Mika Tsujimoto, Peiqi Chen, Akimitsu Miyauchi, Hideaki Sowa, John H. Krege, PINP as an aid for monitoring patients treated with teriparatide, Bone, 2011, 48, 4, 798

    CrossRef

  25. 25
    Bernhard Rintelen, Klaus Bobacz, Günter Höfle, Peter Peichl, Franz Rainer, Kurt Weber, Markus Gaugg, Prophylaxe und Therapie der Glukokortikoid-induzierten Osteoporose – rezente Leitlinien im Überblick, Wiener klinische Wochenschrift, 2011, 123, 21-22, 633

    CrossRef

  26. 26
    Jason R. Maher, Masahiko Takahata, Hani A. Awad, Andrew J. Berger, Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis, Journal of Biomedical Optics, 2011, 16, 8, 087012

    CrossRef

  27. 27
    Steven L. Teitelbaum, Margaret P. Seton, Kenneth G. Saag, Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?, Arthritis & Rheumatism, 2011, 63, 2
    Direct Link:
  28. 28
    Stuart L. Silverman, Keaton Nasser, Teriparitide Update, Rheumatic Disease Clinics of North America, 2011, 37, 3, 471

    CrossRef

  29. 29
    P. Hadji, J. R. Zanchetta, L. Russo, C. P. Recknor, K. G. Saag, F. E. McKiernan, S. L. Silverman, J. Alam, R. T. Burge, J. H. Krege, M. C. Lakshmanan, D. N. Masica, B. H. Mitlak, J. L. Stock, The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures, Osteoporosis International, 2011,

    CrossRef

  30. 30
    Natalie E. Cusano, Aline G. Costa, Barbara C. Silva, John P. Bilezikian, Therapy of Osteoporosis in Men with Teriparatide, Journal of Osteoporosis, 2011, 2011, 1

    CrossRef

  31. 31
    Karen E Hansen, H Alexander Wilson, Carol Zapalowski, Howard A Fink, Salvatore Minisola, Robert A Adler, Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis, Journal of Bone and Mineral Research, 2011, 26, 9
    Direct Link:
  32. 32
    Michael Maricic, Update on Glucocorticoid-Induced Osteoporosis, Rheumatic Disease Clinics of North America, 2011, 37, 3, 415

    CrossRef

  33. 33
    Caroline J. Davidge Pitts, Ann E. Kearns, Update on Medications With Adverse Skeletal Effects, Mayo Clinic Proceedings, 2011, 86, 4, 338

    CrossRef

  34. 34
    David Ontjes, Diet, Nutrients, and Bone Health, 2011,

    CrossRef

  35. 35
    Diane Horowitz, Galina Marder, Richard Furie, Systemic Lupus Erythematosus, 2011,

    CrossRef

  36. 36
    Jennifer M. Grossman, Rebecca Gordon, Veena K. Ranganath, Chad Deal, Liron Caplan, Weiling Chen, Jeffrey R. Curtis, Daniel E. Furst, Maureen McMahon, Nivedita M. Patkar, Elizabeth Volkmann, Kenneth G. Saag, American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Care & Research, 2010, 62, 11
    Direct Link:
  37. 37
    Tarek Sibai, Elise F. Morgan, Thomas A. Einhorn, Anabolic Agents and Bone Quality, Clinical Orthopaedics and Related Research®, 2010, 469, 8, 2215

    CrossRef

  38. 38
    Jean-Pierre Devogelaer, Yves Boutsen, Daniel H. Manicourt, Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men, Current Osteoporosis Reports, 2010, 8, 3, 154

    CrossRef

  39. 39
    Robert L. Jilka, Maria Almeida, Elena Ambrogini, Li Han, Paula K. Roberson, Robert S. Weinstein, Starros C. Manolagas, Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration, Aging Cell, 2010, 9, 5
    Direct Link:
  40. 40
    Mary Beth O’Connell, Laura M Borgelt, Susan K Bowles, Sheryl F Vondracek, Drug-induced osteoporosis in the older adult, Aging Health, 2010, 6, 4, 501

    CrossRef

  41. 41
    B.L. Clarke, Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis: Thirty-Six–Month Results of a Randomized, Double-Blind, Controlled Trial, Yearbook of Endocrinology, 2010, 2010, 223

    CrossRef

  42. 42
    Anthony R. Doyon, Ian K. Ferries, Jiliang Li, Glucocorticoid Attenuates the Anabolic Effects of Parathyroid Hormone on Fracture Repair, Calcified Tissue International, 2010, 87, 1, 68

    CrossRef

  43. 43
    Robert A. Adler, Glucocorticoid-Induced Osteoporosis: Management Update, Current Osteoporosis Reports, 2010, 8, 1, 10

    CrossRef

  44. 44
    Juliet Compston, Management of glucocorticoid-induced osteoporosis, Nature Reviews Rheumatology, 2010, 6, 2, 82

    CrossRef

  45. 45
    Negin Nassabeh, Metabolic bone diseases: Teriparatide or alendronate for glucocorticoid-induced osteoporosis therapy?, Nature Reviews Rheumatology, 2010, 6, 1, 1

    CrossRef

  46. 46
    Marcy B. Bolster, Osteoporosis and Bone Health in Patients with Lung Disease, Clinics in Chest Medicine, 2010, 31, 3, 555

    CrossRef

  47. 47
    J. del Pino Montes, R. Pedrero Ferreras, M.D. Sánchez González, A. Carpio Pérez, R. López González, Seguimiento y tratamiento de la osteoporosis inducida por glucocorticoides, Medicine - Programa de Formación Médica Continuada Acreditado, 2010, 10, 60, 4177

    CrossRef

  48. 48
    Serge Ferrari, Ego Seeman, Hong-Wen Deng, David G Little, Toshio Matsumoto, Clinical and basic research papers – December 2009, IBMS BoneKEy, 2009, 6, 12, 459

    CrossRef

View Full Article (HTML) Get PDF (125K)